FDA Approves Inavolisib with Palbociclib and Fulvestrant for Endocrine-Resistant, PIK3CA-mutated, HR-positive, HER2-negative Advanced Breast Cancer By Ogkologos - November 20, 2024 763 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the INAVO120 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Datopotamab Deruxtecan Improves Survival Over Chemotherapy in Patients with Previously Untreated,... April 28, 2026 The Barriers to Care Faced by LGBTQ People With Cancer: An... January 21, 2021 Improving research with registered reports May 16, 2022 Maintenance Olaparib in Elderly Patients With a Germline BRCA Mutation and... July 1, 2020 Load more HOT NEWS 40 K9 Officers Line Up Outside Terminally Ill Girl’s House For... ¿Cómo están cambiando los requisitos de elegibilidad para los ensayos clínicos... Clinical Trials in Genitourinary Cancers: CheckMate 914, KEYNOTE-992, and KEYNOTE-991 FDA Approves Lorlatinib for Metastatic ALK-positive Non-Small Cell Lung Cancer
